Introduction The oncogene c-Myc is frequently overexpressed in ovarian carcinomas [1]. The small molecule c-Myc inhibitor, 10058-F4, was investigated here to evaluate its effects on ovarian cancer cell growth as well as its mechanism of action [2]. The inhibitor’s impact on apoptosis, cell cycle, cell colony formation, ROS generation, and cell viability were examined in Hey and SKOV3 cell lines. These findings suggest that small molecule c-Myc inhibitors may be a promising strategy for future ovarian cancer therapies. Materials and Methods Cell cycle analysis Hey and SKOV3 cell lines (both human ovarian cancer) were plated in 96-well plates and treated [...]